Category : NationalPublished on: September 08 2022
Share on facebook
The Drugs Controller General of India (DCGI) on Tuesday approved the country’s first intra-nasal Covid-19 vaccine — Bharat Biotech’s iNCOVACC — for restricted emergency use in those aged above 18 years.
It’s only the second such vaccine in the world, after CanSino Biologics’ vaccine in China, to get regulatory approval.
iNCOVACC is a chimpanzee adenovirus vectored recombinant nasal vaccine that has been specifically formulated to allow intra-nasal delivery through nasal drops.
It has been designed to not only protect against infection but also reduce transmission of the virus.
Currently, Covishield, Covaxin and Corbevax are part of the Government’s Covid immunisation drive while vaccines like Covovax and Sputnik are available at private centres.
